# AET05 variant 1 is produced correctly

    Code
      res
    Output
                                                 Placebo          Xanomeline High Dose   Xanomeline Low Dose
                                                 (N=86)                  (N=84)                (N=84)       
      ——————————————————————————————————————————————————————————————————————————————————————————————————————
      Total patient-years at risk                 -0.2                    -1.9                  -2.9        
      Number of adverse events observed            20                      30                    36         
      AE rate per 100 patient-years             -11068.18               -1563.12              -1240.47      
      95% CI                              (-15918.94, -6217.43)   (-2122.47, -1003.78)   (-1645.69, -835.26)

# AET05 variant 2 is produced correctly

    Code
      res
    Output
                                                 Placebo          Xanomeline High Dose   Xanomeline Low Dose
                                                 (N=86)                  (N=84)                (N=84)       
      ——————————————————————————————————————————————————————————————————————————————————————————————————————
      Total patient-years at risk                 -0.2                    -1.9                  -2.9        
      Number of adverse events observed            20                      30                    36         
      AE rate per 100 patient-years             -11068.18               -1563.12              -1240.47      
      95% CI                              (-6760.73, -17093.91)   (-1054.63, -2231.46)   (-868.81, -1717.34)

